The preclinical development of regorafenib for the treatment of colorectal cancer.
作者： Koh Miura , Masayuki Satoh , Makoto Kinouchi , Kuniharu Yamamoto , Yasuhiro Hasegawa
DOI: 10.1517/17460441.2014.924923
关键词:
摘要: … as a RAF1 (CRAF) kinase inhibitor, and consequent studies revealed regorafenib to be a … in VEGFR3 and wild-type BRAF, and regorafenib seemed more potent in RAF1, BRAF(V600E), …
informahealthcare.com参考文章(53)
Lila Adnane, Pamela A. Trail, Ian Taylor, Scott M. Wilhelm, Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature Methods in Enzymology. ,vol. 407, pp. 597- 612 ,(2006) , 10.1016/S0076-6879(05)07047-3
F McPhillips, P Mullen, B P Monia, A A Ritchie, F A Dorr, J F Smyth, S P Langdon, Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. British Journal of Cancer. ,vol. 85, pp. 1753- 1758 ,(2001) , 10.1054/BJOC.2001.2139
Roberta Schmieder, Jens Hoffmann, Michael Becker, Ajay Bhargava, Tina Müller, Nicole Kahmann, Peter Ellinghaus, Robert Adams, André Rosenthal, Karl‐Heinz Thierauch, Arne Scholz, Scott M. Wilhelm, Dieter Zopf, Regorafenib (BAY 73‐4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer International Journal of Cancer. ,vol. 135, pp. 1487- 1496 ,(2014) , 10.1002/IJC.28669
Lesley Best, Peter Simmonds, Chris Baughan, Roger Buchanan, Carol Davis, Ian Fentiman, Steve George, Margot Gosney, John Northover, Chris Williams, , Palliative chemotherapy for advanced or metastatic colorectal cancer Cochrane Database of Systematic Reviews. ,(2000) , 10.1002/14651858.CD001545
U. Naumann, I. Eisenmann-Tappe, U. R. Rapp, The Role of Raf Kinases in Development and Growth of Tumors Recent results in cancer research. ,vol. 143, pp. 237- 244 ,(1997) , 10.1007/978-3-642-60393-8_16
Osamu Yoshida, Yuji Chatani, Toshiro Terachi, Yoshiyuki Kakehi, Rika Hoshino, Yusaku Okada, Osamu Ogawa, Hiroya Oka, Masashi Kawaichi, Michiaki Kohno, Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Research. ,vol. 55, pp. 4182- 4187 ,(1995)
Yeo Hyeon Hwang, Jong Young Choi, Soyoun Kim, Eun Sun Chung, Taeuk Kim, Sang Seok Koh, Bogman Lee, Si Hyun Bae, Jin Kim, Young Min Park, Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatology Research. ,vol. 29, pp. 113- 121 ,(2004) , 10.1016/J.HEPRES.2004.02.009
Clemens C. Cyran, Philipp M. Kazmierczak, Heidrun Hirner, Matthias Moser, Michael Ingrisch, Lukas Havla, Alexandra Michels, Ralf Eschbach, Bettina Schwarz, Maximilian F. Reiser, Christiane J. Bruns, Konstantin Nikolaou, Regorafenib Effects on Human Colon Carcinoma Xenografts Monitored by Dynamic Contrast-Enhanced Computed Tomography with Immunohistochemical Validation PLoS ONE. ,vol. 8, pp. e76009- ,(2013) , 10.1371/JOURNAL.PONE.0076009
Scott M. Wilhelm, Jacques Dumas, Lila Adnane, Mark Lynch, Christopher A. Carter, Gunnar Schütz, Karl-Heinz Thierauch, Dieter Zopf, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity International Journal of Cancer. ,vol. 129, pp. 245- 255 ,(2011) , 10.1002/IJC.25864
W Scheithauer, H Rosen, G V Kornek, C Sebesta, D Depisch, Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. ,vol. 306, pp. 752- 755 ,(1993) , 10.1136/BMJ.306.6880.752